Pediatric Nephrology

, Volume 8, Issue 2, pp 230–249 | Cite as

Lupus nephritis in childhood and adolescence

  • J. Stewart Cameron
Invited Review


Lupus nephritis in childhood usually presents after the age of 10 years, and presentation under 5 years is very rare. More males (F∶M ratio 4.5∶1) are affected than in adult-onset cases, but the ratio is the same in prepubertal and pubertal children. The incidence of clinically evident renal disease is greater at onset than in adults (82%), the usual presentation being with proteinuria, 50% having a nephrotic syndrome. Half the children show World Health Organisation class IV nephritis in renal biopsies. Neuropsychiatric lupus is present at onset in 30%, may complicate 50% at some point and remains a major problem. Prognosis has improved greatly over the past 30 years, at least in part the result of immunosuppressive treatment. Treatment of the initial phase may be guided by the severity of the renal biopsy appearances, more aggressive treatment including cytotoxic agents, i.v. methylprednisolone and perhaps plasma exchange, although the value of exchange is not established. Controversy persists as to the most effective cytotoxic treatment in the acute phase, both oral and i.v. cyclophosphamide and azathioprine being used in different units. In the chronic maintenance phase it seems established both clinically and histologically that addition of a cytotoxic agent improves outcome, but again the drug and route of administration are contentious. Azathioprine has the advantage of being safe for pregnancy and not gonadotoxic, whilst i.v. cyclophosphamide has been demonstrated to improve results over prednisolone alone in controlled trials and has advantages in non-compliant patients. No trial comparing the two regimes has been carried out, and one is needed. Today children much less commonly go into renal failure, and the main causes of actual death (15% of patients over 10 years) are now infections and extra-renal manifestations of lupus, principally neurological. Morbidity of the disease and the treatment remain a major problem, especially when treatment exacerbates complications of the disease itself, such as infections, osteonecrosis, thrombosis, vascular disease and possibly neoplasia.

Key words

Systemic lupus erythematosus Nephritis Prednisolone Plasma exchange Cyclophosphamide Azathioprine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wallace DJ, Dubois EL (1987) Dubois' systemic lupus erythematosus, 3rd edn. Lea and Febinger, PhiladelphiaGoogle Scholar
  2. 2.
    Cameron JS (1993) Lupus and lupus nephritis in children. Adv Nephrol 22:59–119Google Scholar
  3. 3.
    Cameron JS (1992) Lupus nephritis. In: Edelmann CE, Spitzer A, Travis LB, Meadow SR (eds) Pediatric kidney disease, 2nd edn. Little Brown, Boston pp 1407–1465Google Scholar
  4. 4.
    Schoenfeld Y, Isenberg D (1989) The mosaic of autoimmunity. Elsevier, AmsterdamGoogle Scholar
  5. 5.
    Arnett FC, Schulman LE (1976) Studies in familial systemic lupus erythematosus. Medicine (Baltimore) 55:313–322Google Scholar
  6. 6.
    Lehman TJA, McCurdy DK, Bernstein BH, King KK, Hanson V (1989) Systemic lupus erythematosus in the first decade of life. Pediatrics 83:235–239Google Scholar
  7. 7.
    Lévy M, Montes de Oca M, Babron MC (1989) Incidence du lupus érythemateux disséminé de l'enfant en région parisienne. Presse Méd 18:2022Google Scholar
  8. 8.
    Lévy M, Montes de Oca M, Babron MC (1989) Lupus érythemateux disséminé chez l'enfant. Étude collaborative en région parisienne. Journées Parisiennes de Pédiatrie. Flammarion, Paris, pp 52–58Google Scholar
  9. 9.
    Fronek Z, Timmerman LA, Alper CA, Hahn BV, Kalunian K, Peterlin BM, McDevitt HD (1988) Major histocompatibility complex associations with systemic lupus erythematosus. Am J Med 85 [Suppl 6A]:42–44Google Scholar
  10. 10.
    Reveille JD, Schrohenloher RE, Acton RT, Barger BO (1989) DNA analysis of HLA-DR and DQ genes in American blacks with systemic lupus erythematosus. Arthritis Rheum 32:1243–1251Google Scholar
  11. 11.
    Serdula MK, Rhoads GG (1979) Frequency of systemic lupus erythematosus in different ethnic groups in Hawaii. Arthritis Rheum 22:328–333Google Scholar
  12. 12.
    Tejani A, Nicastri AD, Chen C-K, Fikrig S, Gurumurthy K (1983) Lupus nephritis in black and hispanic children. Am J Dis Child 137:481–483Google Scholar
  13. 13.
    Agnello V (1978) Complement deficiency states. Medicine (Baltimore) 57:1–23Google Scholar
  14. 14.
    Roberts JL, Schwartz MM, Lewis EJ (1978) Hereditary C2 deficiency and systemic lupus erythematosus associated with severe glomerulonephritis. Clin Exp Immunol 31:328–338Google Scholar
  15. 15.
    Clemenceau S, Castellano F, Oca MM de, Kaplan C, Danon F, Levy M (1990) C4 null alleles in childhood onset systemic lupus erythematosus. Is there any relationship with renal disease? Pediatr Nephrol 4:207–212Google Scholar
  16. 16.
    Fielder AHL, Walport MJ, Batchelor JR, Rynes RI, Black CM, Dodi IA, Hughes GRV (1983) Family studies of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. BMJ 286:425–428Google Scholar
  17. 17.
    Wilson JG, Fearon DT (1984) Altered expression of complement receptors as a pathogenetic factor in systemic lupus erythematosus. Arthritis Rheum 27:1321–1328Google Scholar
  18. 18.
    Walport M, Ng YC, Lachmann PJ (1987) Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clin Exp Immunol 69: 501–507Google Scholar
  19. 19.
    Yewdall V, Cameron JS, Nathan AW, Neild G, Ogg CS, Williams DG (1983) Systemic lupus erythematosus and IgA deficiency. J Clin Lab Immunol 10:13–18Google Scholar
  20. 20.
    Lawley TJ, Hall RP, Fauci AS, Katz SI, Hamberger MI, Frank MM (1981) Defective Fc receptor functions associated with the haplotype HLA-A1-B8-DRw3 haplotype. N Engl J Med 304: 185–192Google Scholar
  21. 21.
    Couser WG, Salant DJ, Madaio MP, Adler S, Groggel GC (1982) Factors influencing glomerular and tubulointerstitial patterns of injury in SLE. Am J Kidney Dis 2 [Suppl 1]:126–134Google Scholar
  22. 22.
    Alexopoulos E, Cameron JS, Hartley BH (1990) Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 37:100–109Google Scholar
  23. 23.
    Brentjens JR, Sepulveda M, Baliah T, Benzel C, Erlanger BF, Elwood C, Montes M, Hsu KC, Andres GA (1975) Interstitital immune complex nephritis in patients with systemic lupus erythematosus. Kidney Int 7:342–350Google Scholar
  24. 24.
    D'Agati VD, Appel GB, Estes D, Knowles DM II, Pirani CL (1986) Monoclonal antibody identification of infiltrating mononuclear leukocytes in lupus nephritis. Kidney Int 30:573–581Google Scholar
  25. 25.
    Cameron JS (1992) Tubular and interstitial factors in the progression of glomerulonephritis. Pediatr Nephrol 6:292–303Google Scholar
  26. 26.
    Steinman CR (1979) Circulating DNA in systemic lupus erythematosus. Am J Med 67:429–435Google Scholar
  27. 27.
    Rumore PM, Steinman CR (1990) Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 86:69–74Google Scholar
  28. 28.
    Adu D, Dobson J, Williams DG (1981) DNA-anti-DNA circulating complexes in the nephritis of systemic lupus erythematosus. Clin Exp Immunol 43:605–614Google Scholar
  29. 29.
    Koffler D, Agnello V, Kunkel HG (1974) Polynucleotide immune complexes in the serum and glomeruli of patients with systemic lupus erythematosus. Am J Pathol 74:109–122Google Scholar
  30. 30.
    Sasaki T, Hatekayama A, Shibata S, Osaki H, Suzuki M, Horie K, Kitagama Y, Yoshinaga K (1991) Heterogeneity of immune complex derived anti-DNA antibodies associated with lupus nephritis. Kidney Int 39:746–753Google Scholar
  31. 31.
    Termaat R-M, Assmann KJM, Dijkman H, Gompel F van, Smeenk RJT, Berden JHM (1992) Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int 42: 1363–1371Google Scholar
  32. 32.
    Lake HA, Morgan A, Henderson B, Staines NA (1985) A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis Immunology 54:389–395Google Scholar
  33. 33.
    Raz E, Brezis M, Rosenmann E, Eilat D (1989) Anti-DNA antibodies bind directly to renal antigens and induced kidney dysfunction in the isolated perfused rat kidney. J Immunol 142: 3076–3082Google Scholar
  34. 34.
    Frampton G, Hobby P, Morgan A, Staines NA, Cameron JS (1991) A role for DNA in anti-DNA antibodies binding to endothelial cells. J Autoimmunity 4:463–478Google Scholar
  35. 35.
    Chan TM, Frampton G, Staines NA, Hobby P, Perry GJ, Cameron JS (1992) Different mechanisms by which monoclonal anti-DNA antibodies bind to human endothelial cells and glomerular mesangial cells. Clin Exp Immunol 88:68–74Google Scholar
  36. 36.
    Schmiedke TMJ, Stockl FW, Weber R, Sugisaki Y, Batsford SR, Vogt A (1989) Histones have high affinity for the glomerular basement membrane. Relevance for immune complex formation in lupus nephritis. J Exp Med 169:1879–1894Google Scholar
  37. 37.
    Tan EM, Cohen AS, Fries JF, Masi AT, MsShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1992 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1276–1277Google Scholar
  38. 38.
    Barron KS, Person DA, Brewer EJ, Beale MG, Robson AM (1982) Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 101:137–141Google Scholar
  39. 39.
    Caiero F, Michielson MG, Bernstein R, Hughes GRV, Ansell B (1981) Systemic lupus erythematosus in childhood. Ann Rheum Dis 40:325–331Google Scholar
  40. 40.
    Kellum RE, Haserick JK (1964) Systemic lupus erythematosus: a statistical evaluation of mortality based on a consecutive series of 299 patients. Arch Intern Med 113:200–207Google Scholar
  41. 41.
    Cook D, Wedgwood RJP, Craig JM, Hartmann JR, Janeway CA (1961) Systemic lupus erythematosus. Pediatrics 26:570–585Google Scholar
  42. 42.
    Fish AJ, Blau EB, Westberg NG, Burke BA, Vernier RL, Michael AF (1977) Systemic lupus erythematosus within the first two decades of life. Am J Med 62:99–117Google Scholar
  43. 43.
    Garin EH, Donnely WH, Fennell RS, Richard GA (1976) Nephritis of systemic lupus erythematosus in children. J Pediatr 89: 366–371Google Scholar
  44. 44.
    Glidden RS, Manzouranis C, Borel Y (1983) Systemic lupus erythematosus in childhood: clinical manifestations and improved survival in fifty-five patients. Clin Immunol Immunopathol 29: 196–210Google Scholar
  45. 45.
    Gribetz D, Henley WL (1959) Systemic lupus erythematosus in childhood. J Mount Sinai Hosp 26:289–296Google Scholar
  46. 46.
    Hagge WW, Burke EC, Stickler GB (1967) Treatment of systemic lupus erythematosus complicated by nephritis in children. Pediatrics 40:822–827Google Scholar
  47. 47.
    Jacobs JC (1963) Systemic lupus erythematosus in childhood. Pediatrics 32:257–264Google Scholar
  48. 48.
    King KK, Kornreich HK, Bernstein BH, Singsen BH, Hanson V (1977) The clinical spectrum of systemic lupus erythematosus in childhood. Arthritis Rheum 20 [Suppl]:287–293Google Scholar
  49. 49.
    Meislin AG, Rothfield N (1968) Systemic lupus erythematosus in childhood. Analysis of 42 cases, with comparative data on 200 adult cases followed concurrently. Pediatrics 42:37–49Google Scholar
  50. 50.
    Niaudet P, Lévy M (1983) Lupus érythemateux disséminé. In: Royer P, Habib R, Mathieu H, Broyer M (eds) Néphrologie pédiatrique. Flammarion. Paris, pp 351–367Google Scholar
  51. 51.
    Norris DG, Colon AR, Stickler GB (1977) Systemic lupus erythematosus in children. The complex problems of diagnosis and treatment encountered in 101 such patients at the Mayo clinic. Clin Pediatr (Phila) 16:774–778Google Scholar
  52. 52.
    Okawa KI, Wada H, Kobayashi O (1976) Systemic lupus erythematosus in children. Acta Med Biol 23:147–170Google Scholar
  53. 53.
    Peterson RDA, Vernier RL, Good RA (1963) Lupus erythematosus. Pediatr Clin North Am 10:942–978Google Scholar
  54. 54.
    Platt JL, Burke BA, Fish AJ, Kim Y, Michael AF (1982) Systemic lupus erythematosus in the first two decades of life. Am J Kidney Dis 2 [Suppl 1]:212–221Google Scholar
  55. 55.
    Robinson MJ, Williams AL (1967) Systemic lupus erythematosus in childhood. Aust Pediatr J 3:36–47Google Scholar
  56. 56.
    Schaller J (1982) Lupus in childhood. Clin Rheum Dis 8:219–228Google Scholar
  57. 57.
    Wallace C, Schaller JG, Emery H, Wedgwood R (1978) Prospective study of childhood systemic lupus erythematosus (SLE). Arthritis Rheum 21:599–600Google Scholar
  58. 58.
    Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL (1981) Systemic lupus erythematosus-survival patterns. Experience with 609 patients. JAMA 245:934–938Google Scholar
  59. 59.
    Walravens PA, Chase HP (1976) The prognosis of childhood systemic lupus erythematosus. Am J Dis Child 130:929–933Google Scholar
  60. 60.
    Zetterstrom B, Berglund G (1956) Systemic lupus erythematosus in childhood. A clinical study. Acta Paediatr Scand 45:189–204Google Scholar
  61. 61.
    Cameron JS, Chantler C, Haycock G, Hicks J (1984) The nephritis of systemic lupus erythematosus in childhood and adolescence. In Brodehl J, Ehrich JWW (eds) Pediatric nephrology. Springer, New York Berlin Heidelberg, pp 230–236Google Scholar
  62. 62.
    Morris MC, Cameron JS, Chantler C, Turner DR (1981) Systemic lupus erythematosus with nephritis. Arch Dis Child 56:779–783Google Scholar
  63. 63.
    Grossman J, Schwartz RH, Callerame ML, Condemi JI (1975) Systemic lupus erythematosus in a one year old child. Am J Dis Child 129:123–125Google Scholar
  64. 64.
    Desser KB, Sartiano GP, Cooper JL (1969) Lupus livedo and cutaneous infarction. Angiology 20:261Google Scholar
  65. 65.
    Bywaters EGL (1975) Jaccoud's syndrome. A sequel to the joint involvement of systemic lupus erythematosus. Clin Rheum Dis 1: 125–148Google Scholar
  66. 66.
    Galve E, Candell-Riera J, Pigrau C, Permaeyer-Miralda G, Garciadel Castillo H, Soler-Soler J (1988) Prevalence, morphologic types and evolution of cardiac valvular disease in systemic lupus erythematosus. N Engl J Med 319:817–823Google Scholar
  67. 67.
    Leung W-H, Wing K-L, Lau C-P, Wong C-K, Liu H-W (1990) Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89:411–419Google Scholar
  68. 68.
    Case records of the Massachusetts General Hospital (1988) Case no 37-1988. N Engl J Med 319: 699–712Google Scholar
  69. 69.
    Mintz G, Acevedo-Vasquez E, Guterriez-Espinosa G, Avelar-Garnica F (1984) Renal vein thrombosis and inferior vena cava thrombosis in systemic lupus erythematosus. Arthritis Rheum 27: 539–544Google Scholar
  70. 70.
    Miller RW, Salcedo JR, Fink RJ, Murphy TM, Magilavy DB (1986) Pulmonary hemorrhage in pediatric patients with systemic lupus erythematosus. J Pediatr 108:576–579Google Scholar
  71. 71.
    Abramson SB, Dobro J, Eberle M, Benton M, Reibman J, Epstein H, Rapoport DM, Belmont M, Goldring RM (1991) Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 114:941–947Google Scholar
  72. 72.
    Van Dam AP (1991) Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 11:1–11Google Scholar
  73. 73.
    Yancey CL, Doughty RA, Arthreya BH (1981) Central nervous system involvement in childhood systemic lupus erythematosus. Arthritis Rheum 24:1389–1395Google Scholar
  74. 74.
    King J, Aukett A, Smith MF, Hosking G, Milford Ward A, Hughes P (1988) Cerebral systemic lupus erythematosus. Arch Dis Child 63:968–970Google Scholar
  75. 75.
    Lim L, Ron MA, Ormerod IEC, Miller DH, Logsdail SJ, Walport MJ, Harding AE (1988) Psychiatric and neurological manifestations in systemic lupus erythematosus. Q J Med 66:27–38Google Scholar
  76. 76.
    Pinching AJ, Travers RL, Hughes GRV, Jones T, Moss S (1978) Oxygen-15 brain scanning for detection of cerebral involvement. Lancet I:898–900Google Scholar
  77. 77.
    Herd JK, Mehdi M, Uzendoski DM, Saldivar VA (1978) Chorea associated with systemic lupus erythematosus: report of 2 cases and review of the literature. Pediatrics 61:308–313Google Scholar
  78. 78.
    Kukla LF, Reddy C, Silkalns G, Prasad M (1978) Systemic lupus erythematosus presenting as chorea. Arch Dis Child 53:345–347Google Scholar
  79. 79.
    Khamashta MA, Gil A, Anciones B, Lavilla P, Valencia ME, Pintado V, Vasquez JJ (1988) Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 47:681–683Google Scholar
  80. 80.
    McAbee GN, Barasch ES (1990) Resolving MRI lesions in lupus erythematosus selectively involving the brainstem. Pediatr Neurol 6:186–189Google Scholar
  81. 81.
    Becker GJ, Waldburger M, Hughes GRV, Pepys M (1980) Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 39:50–52Google Scholar
  82. 82.
    Honig S, Gorevic P, Weissmann G (1977) C-reactive protein in systemic lupus erythematosus. Athritis Rheum 20:1065–1070Google Scholar
  83. 83.
    Nadorra RL, Nakazato Y, Landing BH (1987) Pathologic features of gastrointestinal tract lesions in childhood onset systemic lupus erythematosus: study of 26 patients with review of the literature. Pediatr Pathol 7:245–259Google Scholar
  84. 84.
    Runyon BA, La Breque DR, Anuras S (1980) The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 69:187–194Google Scholar
  85. 85.
    Miller MH, Urowitz MB, Gladman DD, Blendis LM (1984) The liver in systemic lupus erythematosus. Q J Med 53:401–409Google Scholar
  86. 86.
    Laing TJ (1988) Gastrointestinal vasculitis and pneumatosis intestinalis due to systemic lupus erythematosus: successful treatment with pulse intravenous cyclophosphamide. Am J Med 85: 555–558Google Scholar
  87. 87.
    Shearn MA (1965) Normocholesterolemic nephrotic syndrome of systemic lupus erythematosus. Am J Med 36:250–261Google Scholar
  88. 88.
    Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE (1989) Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 36:266–271Google Scholar
  89. 89.
    Phadke K, Trachtman H, Nicastri A, Chen CK, Tejani A (1984) Acute renal failure as the initial manifestation of systemic lupus erythematosus in children. J Pediatr 105:38–41Google Scholar
  90. 90.
    Fraga A, Gudino J, Ramon-Niembro F, Alarcon-Segovia D (1978) Mixed connective tissue disease in childhood. Am J Dis Child 132:263–265Google Scholar
  91. 91.
    Cameron JS (1991) The platelet in renal disease. In: Page CF (ed) Platelets in health and disease. Blackwell, Oxford, pp 228–260Google Scholar
  92. 92.
    Cameron JS, Frampton G (1990) The “antiphospholipid syndrome” and the “lupus anticoagulant”. Pediatr Nephrol 4: 662–678Google Scholar
  93. 93.
    Frampton G, Hicks J, Cameron JS (1991) Significance of antiphospholipid antibodies in patients with lupus nephritis. Kidney Int 39:1225–1331Google Scholar
  94. 94.
    Montes de Oca MA, Babron MC, Bletry O, Broyer M, Courtecuisse V, Fontaine JL, Loirat C, Mery J-P, Reinert P, Wechsler B, Levy M (1991) Thrombosis in systemic lupus erythematosus: a French collaborative study. Arch Dis Child 66:713–717Google Scholar
  95. 95.
    Shergy WJ, Kredich DW, Pisetsky DS (1988) The relationship of anticardiolipin antibody to disease manifestations in pediatric systemic lupus erythematosus. J Rheumatol 15:1389–1394Google Scholar
  96. 96.
    Alarcon-Segovia D, Deleze'M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, Fernandez L, Ponce de Leon S (1990) Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective study of 500 consecutive patients. Medicine (Baltimore) 68:353–365Google Scholar
  97. 97.
    Asherson RA, Khamashta MA, Gil A, Vasquez JJ, Chan O, Baguley E, Hughes GRV (1989) Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disorders and the primary antiphospholipid syndrome. Am J Med 86:391–399Google Scholar
  98. 98.
    Kant KS, Pollak VE, Weiss MA, Glueck HI, Miller MA, Hess EV (1981) Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine (Baltimore) 60:71–86Google Scholar
  99. 99.
    Gillespie JP, Lindsley C, Linshaw MA, Richardson WP (1981) Childhood systemic lupus erythematosus with negative anti-nuclear antibody test. J Pediatr 98:578–581Google Scholar
  100. 100.
    Enriquez JL, Rajaraman S, Kalia A, Brouhard BH, Travis LB (1988/89) Isolated antinuclear antibody negative lupus nephropathy in young children. Child Nephrol Urol 9:340–346Google Scholar
  101. 101.
    Klein MH, Thorner PS, Yoon S-J, Poucell S, Baumal R (1984) Determination of circulating immune complexes, C3 and C4 complement components and anti DNA antibody in different classes of lupus nephritis. Int J Pediatr Nephrol 5:75–82Google Scholar
  102. 102.
    Singsen BH, Bernstein BH, King KK, Hanson V (1976) Systemic lupus erythematosus in childhood: correlations between changes in disease activity and serum complement levels. J Pediatr 89: 358–365Google Scholar
  103. 103.
    Kerr LD, Adelberg BR, Schulman P, Spiera H (1989) Factor B activation products in patients with systemic lupus erythematosus. Athritis Rheum 32:1406–1413Google Scholar
  104. 104.
    Falk RJ, Dalmasso AP, Kim Y, Lam S, Michael A (1985) Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med 312:1594–1599Google Scholar
  105. 105.
    Sparberg M, Simon N, Greco F del (1969) Intrahepatic cholestasis due to azathioprine. Gastroenterology 57:439–441Google Scholar
  106. 106.
    Kozeny GA, Barr W, Bansal VK, Vertuno LL, Fresco R, Robinson J, Hano JE (1987) Occurrence of renal tubular dysfunction in lupus nephritis. Arch Intern Med 147:891–895Google Scholar
  107. 107.
    Yeung CK, Wong KL, Ng RP, Ng WL (1984) Tubular dysfunction in systemic lupus erythematosus. Nephron 36:84–88Google Scholar
  108. 108.
    Dreyling KW, Wanner C, Schollmeyer P (1990) Control of hyperkalemia with fludrocortisone in a patient with systemic lupus erythematosus. Clin Nephrol 33:179–183Google Scholar
  109. 109.
    Lee FO, Quismorio FP, Troum OM, Anderson PW, Do YS, Hsueh WA (1989) Mechanisms of hyperkalemia in systemic lupus erythematosus. Arch Intern Med 148:397–401Google Scholar
  110. 110.
    Malleson PN (1989) The role of the renal biopsy in childhood onset systemic lupus erythematosus: a viewpoint. Clin Exp Rheumatol 7:563–566Google Scholar
  111. 111.
    Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JHM, Swaak TJG (1990) Contribution of renal biopsy data in predicting outcome in lupus nephritis. Arthritis Rheum 33:970–976Google Scholar
  112. 112.
    Whiting-O'Keefe Q, Henke JE, Shearn MA, Hopper J Jr, Biava CG, Epstein WV (1982) The information content from renal biopsy in systemic lupus erythematosus. Ann Intern Med 96: 718–723Google Scholar
  113. 113.
    Whiting-O'Keefe Q, Riccardi PJ, Henke JE, Shearn MA, Hopper J Jr, Epstein WV (1982) Recognition of information in renal biopsies of patients with lupus nephritis. Ann Intern Med 96: 723–727Google Scholar
  114. 114.
    Churg J, Sobin LH (1982) Renal disease: classification and atlas of glomerular diseases. Igaku Shoin, TokyoGoogle Scholar
  115. 115.
    Austin HA III, Muenz LR, Joyce KM, Antonovych T, Kullik M, Klippel J, Decker J (1983) Prognostic factors in lupus nephritis Contribution of renal histologic data. Am J Med 75:382–391Google Scholar
  116. 116.
    Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA, and the Lupus Nephritis Study Group (1989) Predictive value of renal pathology in diffuse proliferative glomerulonephritis. Kidney Int 36:891–896Google Scholar
  117. 117.
    Hill GS, Hinglais N, Tron F, Bach J-F (1978) Systemic lupus erythematosus. Morphologic correlations with immunologic and clinical data at the time of biopsy. Am J Med 64:61–79Google Scholar
  118. 118.
    Cameron JS (1989) The treatment of lupus nephritis. Pediatr Nephrol 3:350–362Google Scholar
  119. 119.
    Albert DA, Hadler NM, Ropes MW (1979) Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus? Arthritis Rheum 22:945–953Google Scholar
  120. 120.
    Adu D, Cameron JS (1982) Lupus nephritis. Clin Rheum Dis 8: 153–183Google Scholar
  121. 121.
    Cameron JS (1979) The nephritis of systemic lupus erythematosus. In: Kincaid-Smith P, D'Apice AJP, Atkins RC (eds) Progress in glomerulonephritis. Wiley, New York, pp 387–423Google Scholar
  122. 122.
    Cameron JS (1983) The treatment of immunologically mediated renal disease. In: Zabriskie J, Fillit H, Villareal H, Becker EL (eds) Clinical immunology of the kidney. Wiley, New York, pp 407–440.Google Scholar
  123. 123.
    Ginzler EM, Schom K (1988) Outcome and prognosis in sytemic lupus erythematosus. Rheum Clin North Am 14:67–78Google Scholar
  124. 124.
    Pollak VE, Dosekun AK (1982) Evaluation of treatment in lupus nephritis: effect of prednisone. Am J Kidney Dis 2 [Suppl 1]: 170–177Google Scholar
  125. 125.
    Urman JD, Rothfield NF (1977) Corticosteroid treatment in systemic lupus erythematosus. Survival studies. JAMA 238: 2272–2276Google Scholar
  126. 126.
    Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Balow JF (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting outcome. Kidney Int 25: 689–695Google Scholar
  127. 127.
    Holleraft RM, Dubois EL, Lundberg GD, Chandor SB, Gilbert SB, Quismorio FP, Barbour BH, Fria GJ (1976) Renal change in systemic lupus erythematosus with normal renal function. J Rheumatol 3:251–261Google Scholar
  128. 128.
    O'Dell JR, Hays RC, Guggenheim SJ, Steigerwald JC (1985) Systemic lupus erythematosus without clinical renal abnormalities: renal biopsy findings and clinical course. Ann Rheum Dis 44:415–419Google Scholar
  129. 129.
    Leehey DJ, Katz AI, Azaran AH, Aronson AJ, Spargo BH (1982) Silent diffuse lupus nephritis: long term follow-up. Am J Kidney Dis 2 [Suppl 1]:188–196Google Scholar
  130. 130.
    Donadio JV, Burgess JH, Holley KE (1977) Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 56: 527–536Google Scholar
  131. 131.
    Wang F, Looi LM (1984) Systemic lupus erythematosus with membranous nephropathy in Malaysian patients. Q J Med 53: 209–226Google Scholar
  132. 132.
    Pollak VE, Pirani CL, Schwartz FD (1964) The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 64:537–550Google Scholar
  133. 133.
    Lange K, Ores R, Strauss W, Wachstein M (1965) Steroid therapy of systemic lupus erythematosus based on immunological considerations. Arthritis Rheum 8:244–259Google Scholar
  134. 134.
    Smith FG, Witman N, Latta H (1965) Lupus glomerulonephritis. The effect of large doses of corticosteroids on renal function and renal lesions in children. Am J Dis Child 110:302–308Google Scholar
  135. 135.
    Cathcart ES, Idelson BA, Scheinberg MA, Couser WG (1974) Beneficial effects of methylprednisolone “pulse” therapy in diffuse proliferative nephritis. Lancet I:163–166Google Scholar
  136. 136.
    Garin EH, Sleasman HW, Richard GA, Fennell RS (1986) Pulsed methylprednisolone therapy compared to high dose prednisone in systemic lupus erythematosus. Eur J Pediatr 145:380–383Google Scholar
  137. 137.
    Mackworth Young CG, David J, Morgan SH, Hughes GRV (1988) A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus. Ann Rheum Dis 47:496–502Google Scholar
  138. 138.
    Isenberg DA, Morrow WJW, Snaith MC (1982) Methylprednisolone pulse therapy in the treatment of systemic lupus erythematosus. Ann Rheum Dis 41:347–351Google Scholar
  139. 139.
    Ueda N, Yoshikawa T, Chihara M, Kawaguchi S, Niinomi Y, Yasaki T (1988) Atrial fibrillation following methylprednisolone pulse therapy. Pediatr Nephrol 2:29–31Google Scholar
  140. 140.
    Bettinelli A, Paterlini G, Mazzucchi E, Giani M (1991) Seizures and transient blindness following intravenous pulse methylprednisolone in children with primary glomerulonephritis. Child Urol Nephrol 11:41–43Google Scholar
  141. 141.
    Ackerman GL (1970) Alternate day steroid therapy in lupus nephritis. Ann Intern Med 72:511–519Google Scholar
  142. 142.
    Cameron JS, Lessof MH, Ogg CS, Williams BD, Williams DG (1976) Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations, DNA-binding capacity and precipitating anti-DNA antibody. Clin Exp Immunol 25:418–427Google Scholar
  143. 143.
    Wagner L (1976) Immunosuppressive agents in lupus nephritis: a critical analysis. Medicine (Baltimore) 55:239–250Google Scholar
  144. 144.
    Felson DT, Anderson J (1984) Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. N Engl J Med 311:1528–1533Google Scholar
  145. 145.
    Austin HA III, Klippel JH, Balow JE, Riche NGH le, Steinberg A, Plotz PA, Decker JL (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619Google Scholar
  146. 146.
    Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone alone. Arthritis Rheum 34:945–950Google Scholar
  147. 147.
    Balow JE, Austin HA, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, Steinberg AD, Plotz PH, Decker JL (1984) Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 311:491–495Google Scholar
  148. 148.
    Wall RL, Clausen KP (1975) Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med 293: 271–273Google Scholar
  149. 149.
    Grunwald H, Rosner F (1979) Acute leukemia and immunosuppressive drug therapy for non-neoplastic diseases. Arch Intern Med 139:461–466Google Scholar
  150. 150.
    Trompeter RS, Evans PR, Barratt TM (1981) Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods. Lancet I:1177–1179Google Scholar
  151. 151.
    Stilwell TJ, Benson RC, Remee RA de, McDonald TJ, Weiland LH (1988) Cyclophosphamide induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 31:465–470Google Scholar
  152. 152.
    Epstein WV, Grausz H (1974) Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus. Arthritis Rheum 17:129–142Google Scholar
  153. 153.
    Snaith ML, Holt JM, Oliver DO, Dunhill MO, Halley W, Stephenson AC (1973) Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil. BMJ 2: 197–201Google Scholar
  154. 154.
    Cameron JS (1977) Chlorambucil and leukemia (letter). N Engl J Med 296:1055Google Scholar
  155. 155.
    Balow JE (1990) Treatment and monitoring of patients with lupus nephritis. Nephrol Dial Transplant 5 [Suppl 1]:58–59Google Scholar
  156. 156.
    Kimura Y, Foeldyari I, Jacobs JC (1991) Azathioprine is a valuable agent in the treatment of pediatric lupus (abstract). Pediatr Res 29:345AGoogle Scholar
  157. 157.
    Ponticelli C, Zucchelli P, Moroni G, Cagnoli L, Banfi G, Pasquali S (1987) Long-term prognosis of diffuse lupus nephritis. Clin Nephrol 28:263–271Google Scholar
  158. 158.
    Lehman TJA, Sherry DD, Wagner-Weiner L, McCurdy DK, Emery HM, Magilavy DB, Kovalevsky A (1989) Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J Pediatr 114:1055–1060Google Scholar
  159. 159.
    Gibbons RB, Westerman E (1988) Acute nonlymphocytic leukemia following short term, intermittent intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum 31:1552–1554Google Scholar
  160. 160.
    Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M (1978) Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 21:37–44Google Scholar
  161. 161.
    Sharon E, Kaplan D, Diamond HS (1973) Exacerbation of systemic lupus erythematosus after withdrawal of azathioprine therapy. N Engl J Med 288:122–124Google Scholar
  162. 162.
    Kinlen LJ, Sheil AGR, Peto J, Doll R (1979) Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppression. BMJ 2:1461–1466Google Scholar
  163. 163.
    Lipsmeyer EA (1972) Development of malignant cerebral lymphoma in a patient with systemic lupus erythematosus treated with immunosuppression. Arthritis Rheum 15:183–186Google Scholar
  164. 164.
    Nogueira JH, Freedman MA (1972) Acute pancreatitis as a complication of Imuran therapy in regional enteritis. Gastroenterology 62:1040–1041Google Scholar
  165. 165.
    Sparberg M, Simon N, Greco F del (1969) Intrahepatic cholestasis due to azathioprine. Gastoenterology 57:439–441Google Scholar
  166. 166.
    Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741–745Google Scholar
  167. 167.
    Rothenberg RJ, Graziano FM, Gandone JT, Goldberg JW, Bjarnason DF, Finesilver AG (1988) The use of methotrexate in steroid resistant systemic lupus erythematosus. Arthritis Rheum 31:612–615Google Scholar
  168. 168.
    Leaker BR, Becker GJ, Dowling JP, Kincaid Smith P (1986) Rapid improvement in severe lupus glomerular lesions following intensive plasma exchange associated with immunosuppression. Clin Nephrol 25:236–244Google Scholar
  169. 169.
    Lewis EJ, Hunsicker LG, Lan S-P, Rohde RD, Lachin JM (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 326:1373–1379Google Scholar
  170. 170.
    Wei N, Klippel JH, Huston DP, Hall RP, Lawley TJ, Balow JE, Steinberg AD, Decker EL (1983) Randomized trial of plasma exchange in mild systemic lupus erythematosus. Lancet 1:17–21Google Scholar
  171. 171.
    Dau PC, Callahan J, Parker R, Golbus J (1991) Immunologic effects of plasmapheresis synchronized with pulse cyclophosphamide in systemic lupus erythematosus. J Rheumatol 18: 270–276Google Scholar
  172. 172.
    Schroeder JO, Euler HH, Loffler H (1987) Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Ann Intern Med 107:344–346Google Scholar
  173. 173.
    Clark WF, Lindsay RM, Ulan RA, Cordy PE, Linton AL (1981) Chronic plasma exchange therapy in SLE nephritis. Clin Nephrol 16:20–23Google Scholar
  174. 174.
    Cohen J, Pinching AJ, Rees AJ, Peters DK (1982) Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 51: 1–15Google Scholar
  175. 175.
    Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S (1980) Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 244:2423–2426Google Scholar
  176. 176.
    Pohl MA, Lan S-P, Berl T, and the lupus nephritis collaborative study group (1991) Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. Ann Intern Med 114:924–929Google Scholar
  177. 177.
    Jordan SC, Ho W, Ettenger R, Salusky IB, Fine RN (1987) Plasma exchange improves the glomerulonephritis of systemic lupus erythematosus in selected pediatric patients. Pediatr Nephrol 1:276–280Google Scholar
  178. 178.
    Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE (1992) Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 81:975–984Google Scholar
  179. 179.
    Remuzzi G, Rossi E (eds) (1988) Haemostasis and renal disease. Butterworth, LondonGoogle Scholar
  180. 180.
    Cade R, Spooner G, Schlein G, Pickering M, Quesada A de, Holcomb A, Juncos L, Richard G, Sivres O, Levin D, Hackett R, Free J, Hunt R, Fregly M (1973) Comparison of azathioprine, prednisolone and heparin alone or combined in treating lupus nephritis. Nephron 10:37–56Google Scholar
  181. 181.
    Conte J, Mignon-Conte M, Suc J-M (1973) Réflexions critiques sur le traitement de la néphropathie lupique. Etude comparée de l'action des corticoïdes, de l'association indomethacine-anti-paludéen de synthese, et de l'heparine. J Urol Nephrol 4–5: 333–350Google Scholar
  182. 182.
    Parbtani A, Frampton G, Kasai N, Yewdall V, Cameron JS (1980) Platelet and plasma serotonin concentrations in glomerulone-phritis III. The nephritis of systemic lupus erythematosus. Clin Nephrol 14:164–172Google Scholar
  183. 183.
    Dosekun AK, Pollak VE, Glas-Greenwalt P, Kant S, Penovich P, Lebron Berger A, Weiss MA, Levinson JE (1984) Anterod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolytic effect. Arch Intern Med 144:37–42Google Scholar
  184. 184.
    Kant KS, Pollak VE, Dosekun AK, Glas-Greenwalt P, Weiss MA, Glueck RI (1982) Lupus nephritis with thrombosis and abnormal fibrinolysis: effect of ancrod. J Lab Clin Med 105:77–88Google Scholar
  185. 185.
    Kim S, Wadwha NK, Kant KS, Pollak VE, Glas-Greenwalt P, Weiss MA, Hong CD (1988) Fibrinolysis in glomerulonephritis treated with ancrod: renal functional, immunologic and histopathologic effects. Q J Med 69:879–895Google Scholar
  186. 186.
    Kimberly RP, Gill JR, Bowden RE, Keiser HR, Plotz PH (1978) Elevated urinary prostaglandins and the effects of aspirin in lupus erythematosus. Ann Intern Med 89:336–341Google Scholar
  187. 187.
    Bender WL, Whelton A, Beschorner WE, Darwish MO, Hall-Craggs M, Solez K (1984) Interstitial nephritis, proteinuria, and renal failure caused by non-steroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. Am J Med 76:1006–1012Google Scholar
  188. 188.
    Pierucci A, Simonetti BM, Pecci G, Mavrikakis G, Feriozzi S, Cinotti GA, Patrigiani P, Ciabattoni G, Patrono C (1989) Improvement of renal function with selective thromboxane antagonism in lupus nephritis. N Engl J Med 320:421–425Google Scholar
  189. 189.
    Hariharan S, Pollak VE, Kant KS, Weiss MA, Wadhwa NK (1990) Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod. Clin Nephrol 34:61–69Google Scholar
  190. 190.
    Israel-Biet D, Noel L-H, Bach MA, Dardenne M, Bach JF (1983) Marked reduction of DNA antibody and glomerulopathy in thymulin or cyclosporin A-treated (NZB X NZW) mice. Clin Exp Immunol 54:359–365Google Scholar
  191. 191.
    Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ (1989) Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 9 [Suppl 1]:57–60Google Scholar
  192. 192.
    Feutren G, Querin S, Noel LH, Chatenoud L, Beaurain G, Lesavre P, Bach JF (1987) Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 111:1063–1068Google Scholar
  193. 193.
    Le Francois N, Deleix P, Laville M, Zech P, Traeger J (1984) Treatment of lupus nephritis with cyclosporin A: a patient with a 1 year follow-up (abstract). Kidney Int 26:225Google Scholar
  194. 194.
    Meyrier A (1989) Treatment of glomerular disease with cyclosporin A. Nephrol Dial Transplant 4:923–931Google Scholar
  195. 195.
    Takabayashi K, Koike T, Kurasawa K, Matsumua R, Sato T, Tomioka H, Ito I, Yoshiki T, Yoshida S (1989) Effect of FK-506, a novel immunosuppressive drug, on murine systemic lupus erythematosus. Clin Immunol Immunopathol 51:110–117Google Scholar
  196. 196.
    Leaker B, Quist R, Salehi N, Kincaid Smith PS (1986) The effect of eicosapentanoic acid on active lupus nephritis (abstract). Kidney Int 30:629Google Scholar
  197. 197.
    Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P (1989) Omega-3 fatty acid dietary supplementation in patients with systemic lupus erythematosus (SLE). Kidney Int 36: 653–660Google Scholar
  198. 198.
    Walton AJE, Snaith ML, Locniskar M, Cumberland AG, Morrow WJW, Isenberg DA (1991) Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus. Ann Rheum Dis 50:463–466Google Scholar
  199. 199.
    Haider YS, Roberts WC (1981) Coronary arterial disease in systemic lupus erythematosus. Am J Med 70:775–781Google Scholar
  200. 200.
    Correia P, Cameron JS, Lian JD, Hicks J, Ogg CS, Williams DG, Chantler C, Haycock G (1985) Why do patients with lupus nephritis die? BMJ 290:126–131Google Scholar
  201. 201.
    Westberg G, Tarkowski A (1990) Effect of maxEPA in patients with SLE. Scand J Rheumatol 19:137–143Google Scholar
  202. 202.
    El-Habib R, Laville M, Traeger J (1984) Specific adsorption of circulating antibodies by extracorporeal plasma perfusions over antigen coated collagen flat membranes: applications to systemic lupus erythematosus. J Clin Lab Immunol 15:111–117Google Scholar
  203. 203.
    Palmer A, Gjorstrup P, Severn A, Welsh K, Taube D (1988) Treatment of systemic lupus erythematosus by extracorporeal immunoadsorption (letter). Lancet II:272Google Scholar
  204. 204.
    Terman DS, Buffaloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ayus JC (1979) Extracorporeal immunoadsorption: initial experience in human systemic lupus erythematosus. Lancet II: 824–827Google Scholar
  205. 205.
    Schwartz SA (1990) Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol 10:81–89Google Scholar
  206. 206.
    Jordan SC (1989) Intravenous γ globulin therapy in systemic lupus erythematosus and immune complex disease. Clin Immunol Immunopathol 53 [Suppl]:S164-S169Google Scholar
  207. 207.
    Lin C-Y, Hsu H-C, Chiang H (1989) Improvement in histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 53:303–310Google Scholar
  208. 208.
    Schifferli J, Leski M, Favre H, Imbach P, Nydegger U, Davies K (1991) High dose intravenous IgG treatment and renal function. Lancet 337:457–458Google Scholar
  209. 209.
    Strober S, Field E, Hoppe RT, Kotzin BL, Shemesh O, Engelman E, Ross JC, Myers BD (1985) Treatment of intractable lupus nephritis with total lymphoid irradiation. Ann Intern Med 102: 450–458Google Scholar
  210. 210.
    Strober S (1987) Total lymphoid irradiation in alloimmunity and autoimmunity. J Pediatr 111:1051–1055Google Scholar
  211. 211.
    Strober S, Farinas MC, Field EH, Salovera JT, Kiberd BA, Myers BD, Hoppe RT (1987) Lupus nephritis after total lymphoid irradiation. Persistent improvement and reduction in steroid dosage. Ann Intern Med 197:689–691Google Scholar
  212. 212.
    Steinberg AD, Gourley MF, Klinman DM, Tsokos GC, Scott DE, Krieg AM (1991) NIH conference: systemic lupus erythematosus. Ann Intern Med 115:548–559Google Scholar
  213. 213.
    Hahn B, Ebling FM (1981) Suppression of NZB/NZW murine nephritis by administration of a syngeneic monoclonal antibody to DNA. J Clin Invest 71:1728–1736Google Scholar
  214. 214.
    Hahn BH, Ebling FM (1984) Suppression of murine lupus nephritis by administration of an anti-idiotypic antibody to anti-DNA. J Immunol 132:187–190Google Scholar
  215. 215.
    Wofsy D, Seaman WE (1987) Reversal of advanced murine lupus in NZB/NZW F1 mice with monoclonal antibody to L3T4. Immunol 138:3247–3253Google Scholar
  216. 216.
    Adelman NE, Watling DL, McDevitt HO (1983) Treatment of (NZB X NZW) F1 disease with anti I-A monclonal antibodies. J Exp Med 158:1350–1355Google Scholar
  217. 217.
    Vladitiu AO (1991) Treatment of autoimmune diseases with antibodies to class II major histocompatibility complex antigens. Clin Immunol Immunopathol 61:1–17Google Scholar
  218. 218.
    Kelley VE, Gaulton GN, Hattori M, Ikegami H, Eisenbarth G, Strom TB (1988) Anti-interleukin 2 receptor antibody suppresses murine diabetic insulitis and lupus nephritis. J Immunol 140: 59–61Google Scholar
  219. 219.
    Adorini L, Barnaba V, Bona C, Celada F, Lanzavecchia A, Sercarz E, Suciu-Foca N, Wekerle H (1990) New perspectives on immunointervention in autoimmune diseases. Immunol Today 11:383–386Google Scholar
  220. 220.
    Kinglsey G, Panayi G, Lanchbury J (1991) Immunotherapy of rheumatic diseases-practice and prospects. Immunol Today 12: 177–179Google Scholar
  221. 221.
    Pankewycz O, Strom TB, Kelley VE (1989) Therapeutic strategies using monoclonal antibodies in autoimmune disease. Curr Opinion Immunol 1:757–763Google Scholar
  222. 222.
    Winter G, Milstein C (1991) Man-made antibodies. Nature 349: 293–299Google Scholar
  223. 223.
    Kelley VE, Bacha P, Pankewycz O, Nichols JC, Murphy JR, Strom TB (1988) Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci USA 85:3980–3984Google Scholar
  224. 224.
    Lederboum-Glaski H, FitzGerald D, Chaudhary V, Adhya S, Pastan I (1988) Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced inEscherichia coli. Proc Natl Acad Sci USA 85, 1922–1926Google Scholar
  225. 225.
    Ponticelli C, Moroni G, Banfi G, Ponticelli C (1988) Discontinuation of therapy in diffuse proliferative lupus nephritis (letter). Am J Med 85:275Google Scholar
  226. 226.
    Tozman ECS, Urowitz MB, Gladman DD (1982) Prolonged complete remission in previously severe SLE. Ann Rheum Dis 41:39–40Google Scholar
  227. 227.
    Studenski S, Allen NB, Caldwell DS, Rice JR, Pilisson RP (1987) Survival in systemic lupus erythematosus. A multivariate analysis of demographic factors. Arthritis Rheum 30:1326–1332Google Scholar
  228. 228.
    Liang MH, Partridge AJ, Daltroy LH, Straaton KV, Galper SR, Holman HR (1991) Strategies for reducing excess morbidity and mortality in blacks with systemic lupus erythematosus. Arthritis Rheum 34:1187–1196Google Scholar
  229. 229.
    Appel GB, Cohen DJ, Pirani CL, Melzer JI, Estes D (1987) Long term follow up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 83:877–885Google Scholar
  230. 230.
    Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kachgarian M (1989) The clinical an renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 72:779–833Google Scholar
  231. 231.
    Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL) (1992) Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 19:473–479Google Scholar
  232. 233.
    Ginzler EM, Diamond HS, Weiner M, Schelsinger M, Fries JF, Wasner C, Medsger TA, Ziegler G, Klippel JH, Hadler NM, Alabert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV (1982) A multicentre study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 25:601–611Google Scholar
  233. 234.
    Leaker B, Fairley KF, Dowling J, Kincaid-Smith P (1987) Lupus nephritis: clinical and pathological correlation. Q J Med 62: 163–179Google Scholar
  234. 235.
    Lévy M (1991) Les evolutions défavorables au cours du lupus érythemateux disséminé de l'enfant. Ann Pediatr (Paris) 38: 434–439Google Scholar
  235. 236.
    Gordon MF, Stolley PD, Schinnar K (1981) Trends in recent systemic lupus erythematosus mortality rates. Arthritis Rheum 24:762–769Google Scholar
  236. 237.
    Celermajer DS, Thorner PS, Baumal R, Arbus GS (1984) Sex differences in childhood lupus nephritis. Am J Dis Child 138: 586–588Google Scholar
  237. 238.
    Rush PJ, Baumal R, Shore A, Balfe JW, Schreiber M (1986) Correlation of renal histology with outcome in children with lupus nephritis. Kidney Int 29:1066–1071Google Scholar
  238. 239.
    Dujovne I, Pollak VE, Pirani CL, Dillard MG (1972) The distribution and character of glomerular deposits in systemic lupus erythematosus. Kidney Int 2:33–50Google Scholar
  239. 240.
    Tateno S, Kobayashi Y, Shigematsu H, Hiki Y (1983) Study of lupus nephritis: its classification and the significance of subendothelial deposits. Q J Med 52:311–331Google Scholar
  240. 241.
    Muehrcke RC, Kark RM, Pirani CL, Pollak VE (1957) Lupus nephritis: a clinical and pathologic study based on renal biopsies. Medicine (Baltimore) 36:1–119Google Scholar
  241. 242.
    Park MH, D'Agati V, Appel GB, Pirani CL (1986) Tubulointerstitial disease in lupus nephritis: relation to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 44:309–319Google Scholar
  242. 243.
    Magil AB, Puterman ML, Ballon HS, Chan V, Lierenman DS, Rae A, Sutton RAL (1988) Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 34:511–517Google Scholar
  243. 244.
    Abeles M, Urman JD, Weinstein A, Lowenstein M, Rothfield NF (1980) Systemic lupus erythematosus in the younger patientß: survival studies. J Rheumatol 7:515–522Google Scholar
  244. 245.
    Lacks S, White P (1990) Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol 17:941–945Google Scholar
  245. 246.
    Karsh J, Klippel JH, Balow JE, Decker JL (1979) Mortality in lupus nephritis. Arthritis Rheum 22:274–769Google Scholar
  246. 247.
    Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA, Ziegler G, Klippel G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV (1982) A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 25:612–617Google Scholar
  247. 248.
    Staples PJ, Gerding DN, Decker JL, Gordon RS (1974) Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 17:1–10Google Scholar
  248. 249.
    Nived O, Sturfelt G, Wollheim F (1985) Systemic lupus erythematosus and infection: a controlled and prospective study including epidemiological data. Q J Med 55:271–287Google Scholar
  249. 250.
    Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H (1990) High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 49:630–633Google Scholar
  250. 251.
    Lehman TJA, Palmeri ST, Hastings C, Klippel JH, Plotz PH (1983) Bacterial endocarditis complicating systemic lupus erythematosus. J Rheumatol 10:655–658Google Scholar
  251. 252.
    Haselaar P, Derksen RHWM, Blokzijl L, Hessing M, Nieuwenhuis HK, Bouma BN, Groot PG de (1989) Risk factors for thrombosis in lupus patients. Ann Rheum Dis 48:933–940Google Scholar
  252. 253.
    Angles-Cano E, Sultan Y, Clavel J (1979) Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation to endothelial cell damage. J Lab Clin Med 94:312–323Google Scholar
  253. 254.
    Byron MA, Allington MJ, Chapel HM, Mowat AG, Cederhohn, Williams SA (1987) Indications of vascular cell endothelial cell dysfunction in systemic lupus erythematosus. Ann Rheum Dis 46:741–745Google Scholar
  254. 255.
    Cole EH, Schulman J, Urowitz M, Keystone E, Williams C, Levy GA (1985) Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus. J Clin Invest 75: 861–868Google Scholar
  255. 256.
    Gelfand J, Truong L, Stern L, Pirani CL, Appel GB (1985) Thrombotic thrombocytopenic purpura syndrome in systemic lupus erythematosus: treatment with plasma exchange. Am J Kidney Dis 6:154–160Google Scholar
  256. 257.
    Itoh Y, Sekine H, Honoso O, Takeuchi T, Koide J, Takano M, Abe T (1990) Thrombotic thrombocytopenic purpura in two patients with systemic lupus erythematosus: clinical significance of anti platelet antibodies. Clin Immunol Immunopathol 57: 125–136Google Scholar
  257. 258.
    Weiner ES, Abeles M (1989) Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus; a reevaluation. J Rheumatol 16:604–608Google Scholar
  258. 259.
    Nagasawa K, Ishii Y, Mayumi T, Tada T, Ueda A, Yamauchi Y, Kusaba T, Niho Y (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48:672–676Google Scholar
  259. 260.
    Felson DT, Anderson JJ (1987) A cross study evaluation of association between steroid dose and bolus steroids and avascular necrosis of bone. Lancet I:902–906Google Scholar
  260. 261.
    Zizic TM, Hungerford DS, Stevens MB (1980) Ischemic bone necrosis in systemic lupus erythematosus. I. early diagnosis of ischemic necrosis of bone. II. The treatment of ischemic necrosis of bone in systemic lupus erythematosus. Medicine (Baltimore) 59:134–148Google Scholar
  261. 262.
    Bergstein JM, Wiens C, Fish AJ, Vernier RL, Michael A (1974) Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr 85:31–35Google Scholar
  262. 263.
    Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60:221–225Google Scholar
  263. 264.
    Ishikawa S, Segar WE, Gilbert EF, Burkholder PM, Levy JM, Visekul C (1978) Myocardial infarct in a child with systemic lupus erythematosus. Am J Dis Child 132:696–699Google Scholar
  264. 265.
    Bulkley HB, Roberts WC (1975) The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. Am J Med 58:243–264Google Scholar
  265. 266.
    Ilowite NT, Samual P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863Google Scholar
  266. 267.
    Ostrov BE, Min W, Eichenfeld AH, Goldsmith DP, Kaplan B, Athreya BH (1989) Hypertension in children with systemic lupus erythematosus. Semin Arthritis Rheum 19:90–98Google Scholar
  267. 268.
    Delgado EA, Malleson PN, Pirie GE, Pretty RE (1990) The pulmonary manifestations of childhood onset systemic lupus erythematosus. Semin Arthritis Rheum 19:285–293Google Scholar
  268. 269.
    Pohlgeers AP, Eid NS, Shikler KN, Shearer LT (1990) Systemic lupus erythematosus: pulmonary presentation in childhood. South Med J 83:712–714Google Scholar
  269. 270.
    Canoso JJ, Cohen AS (1974) Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum 17: 383–390Google Scholar
  270. 271.
    Lewis RB, Castor CW, Knisley RE, Bole GG (1976) Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 19:1256–1260Google Scholar
  271. 272.
    Carlow TJ, Glaser JS (1974) Pseudotumor cerebri syndrome in systemic lupus erythematosus. JAMA 228:197–200Google Scholar
  272. 273.
    Askari A, Vignos PJ, Moskowitz RW (1976) Steroid myopathy in connective tissue diseases. Am J Med 61:485–492Google Scholar
  273. 274.
    Watson RM, Lane AT, Barnett NK, Bias WB, Arnett FC, Provost TT (1984) Neonatal lupus erythematosus. A clinical serological and immunological study with review of the literature. Medicine (Baltimore) 63:362–378Google Scholar
  274. 275.
    Maddison PJ (1990) Anti-Ro antibodies and neonatal lupus. Clin Rheumatol 9 [Suppl 1]:116–122Google Scholar
  275. 276.
    Lehman TJA, Reichlin M, Santner TJ, Silverman E, Petty RE, Spencer CH, Hawley JB (1989) Maternal antibodies to Ro (SS-A) are associated with both early onset of disease and male sex among children with systemic lupus erythematosus. Arthritis Rheum 32:1414–1420Google Scholar
  276. 277.
    Jackson R, Gulliver M (1979) Neonatal lupus erythematosus progressing into systemic lupus erythematosus. Br J Dermatol 101:81–86Google Scholar
  277. 278.
    Scott JS, Maddison PJ, Taylor PV, Esscher E, Scott O, Skinner RP (1983) Connective tissue disease, antibodies to ribonucleoprotein, and congenital heart block. N Engl J Med 309:209–212Google Scholar
  278. 279.
    Van Kerkhove C (1990) Lupus erythematosus in childhood: effect of maternal factors beyond neonatal disease? Clin Rheumatol 9:168–170Google Scholar
  279. 280.
    Arnaiz-Virella A, Vasquez-Rodriguez JJ, Vicario JL, Livilla P, Pascual D, Moreno F, Martinez-Laso J (1989) Congenital heart block immunogenetics. Evidence for an additional role of HLA class III antigens and independence of Ro antibodies. Arthritis Rheum 32:1421–1426Google Scholar
  280. 281.
    Oviasu E, Hicks J, Cameron JS (1991) The outcome of pregnancy in women with lupus nephritis. Lupus 1:19–25Google Scholar

Copyright information

© IPNA 1994

Authors and Affiliations

  • J. Stewart Cameron
    • 1
  1. 1.Renal Unit, Clinical Science LaboratoriesGuy's HospitalLondonUK

Personalised recommendations